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Bladder augmentation was first described in 1899. The goal at the time was to establish
the ideal method to create a simple capacious reservoir for the safe storage of urine. That
simple idea has over the last 100 years grown into one of the most dynamic areas in Pedi-
atric Urology. Creative minds and hands from individuals in multiple disciplines have led us
from creating a reservoir to the threshold of recreating a functional organ. In this review,
we look at the historical evolution of bladder augmentation and how it exponentially grew
in scope from those initial descriptions of intestinocystoplasty to the work being reported
today in the field of tissue engineering.
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INTRODUCTION
The evolution of bladder augmentation is now well over 100 years
old. The technique was first applied to patients and reported
independently by both Rutkowski and Mikulicz in 1899. Each
described ileocystoplasty, either as a single or staged procedure,
in a patient with bladder exstrophy (1, 2). Rutkowski felt that with
bowel we had out ideal material for cystoplasty while Mikulicz
cautioned that it was the final functional outcome obtained by
the procedure that would determine its value. Since these initial
reports, we have been witness to a myriad of technical and scientific
innovations in people’s attempts to develop the optimal technique
and material for bladder augmentation. The creative minds and
skillful hands of countless people have taken us far beyond those
initial goals of simply trying to create a larger reservoir and have
moved us to the field of tissue engineering and bladder regenera-
tion. Oliver Wendell Holmes Jr. felt that “man’s mind stretched to
a new idea, never goes back to its original dimensions.” Since those
initial papers published by Rutkowski and Mikulicz more than a
century ago, the field of bladder augmentation has certainly held
true to this.
ENTEROCYSTOPLASTY
ILEO- AND COLOCYSTOPLASTY
The objective of bladder augmentation is to create a low-pressure
storage reservoir of sufficient capacity to preserve upper urinary
tract function and maintain or establish urinary continence when
maximal medical therapy is unsuccessful. In this respect, blad-
der augmentation using ileum or colon reconfigured to create a
spherical final configuration has proven to be a reliable means of
increasing bladder capacity and reducing bladder pressures (3–8).
However, the incorporation of these intestinal segments into the
urinary tract soon highlighted the fact that patients were at risk for
a number of long-term complications attributable to the presence
of intestinal mucosa (9). This was directly attributable to the differ-
ences in absorptive and secretory properties between urothelium
and bowel mucosa. The typically impermeable characteristics of
the urothelium were being altered. Furthermore with the young
patient population usually being treated, the long-term exposure
to these complications heightened the concern. The complications
most commonly observed included mucus production, bacterial
colonization, electrolyte imbalances, metabolic acidosis, somatic
growth retardation, vitamin B12 deficiency, and the formation of
bladder calculi (10–20). The potential to develop a malignancy
became a significant concern and a number of reports were pub-
lished to this effect over the years (21–23). A recent analysis by
Higuchi et al. however evaluated 153 patients with an ileal/colonic
cystoplasty and a matched control population. The authors found
that patients with congenital bladder dysfunction undergoing
ileal/colonic bladder augmentation do not appear to increase their
risk of bladder malignancy over the inherent risk associated with
the underlying congenital anomaly alone. It seems that the con-
genital dysfunctional bladder alone represents the increased risk
for malignancy (24).
GASTROCYSTOPLASTY
Sinaiko first described gastrocystoplasty using stomach for urinary
diversion in a dog model (25). The technique was first introduced
clinically by Leong and Ong (26, 27). In North America, gastro-
cystoplasty was introduced as an alternative to colon or ileum
in children with chronic renal failure and azotemia as a direct
result of its natural acid secreting ability. This did not worsen the
metabolic acidosis as was typically seen with ileum or colon (28).
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The technique was also useful when bowel resection was not an
option, as is the case with short-bowel syndrome. Mucus produc-
tion was less problematic and the acidic urine could also reduce
bacterial colonization and the incidence of urinary tract infections.
Specific complications have become apparent however and include
intermittent hematuria, metabolic alkalosis, and the hematuria–
dysuria syndrome. This is characterized by bladder or urethral
pain and hematuria in the absence of infection (29, 30). Further-
more, children with incontinence or renal insufficiency/oliguria
tend to experience more problems with the hematuria–dysuria
syndrome. Since the hematuria–dysuria syndrome does not always
respond well to histamine antagonists, this may pose a significant
problem in children with normal bladder and urethral sensation.
An additional concern is that the inherent metabolic acidosis in
patients with renal insufficiency reverses with renal transplanta-
tion. The presence of a gastrocystoplasty in this situation creates a
tendency toward metabolic alkalosis; a problem significantly more
challenging to manage medically. The frequency and severity of
complications after gastrocystoplasty has resulted in the proce-
dure losing favor and has led some to recommend abandoning it
altogether (31). The majority of malignancies have been reported
in patients undergoing enterocystoplasty but malignancies fol-
lowing gastrocystoplasty have been reported (32–36). One such
report observed a 14- to 15-fold increased risk for the development
of bladder cancer over standard norms (36). To date there have
been no studies examining whether augmentation gastrocysto-
plasty increases the risk of bladder malignancy over that inherent
to a congenitally abnormal bladder however.
UROTHELIAL PRESERVING AUGMENTATION TECHNIQUES
Marucci and Shoemaker described the characteristics of the deal
segment for bladder augmentation/substitution in 1955 (37, 38).
Conceptually, they felt that the ideal material should:
- be easily available
- allow large areas to be potentially used
- be easily mobilized without jeopardizing its blood supply
- allow regrowth of urothelium
- have sufficient pliability to assume the shape of the bladder
- have an inherent functioning bladder layer
- not absorb electrolytes or nitrogenous wastes of the urine
- not produce mucus or irritating substances.
This spurred the reporting of numerous creative techniques for
urinary reconstruction. Most of these procedures used part of the
alimentary tract for this purpose. Several alternatives to the use
of bowel or stomach were proposed. All of them had the com-
mon goal of eliminating or diminishing the problems associated
with the incorporation of gastrointestinal mucosa into the urinary
tract. The variety of natural materials used has included peri-
toneum (39), omentum (40, 41), fascial free grafts (42), lyophilized
human dura (43), bovine pericardium (44) fresh placental mem-
branes (45), and preserved bladder grafts (46), as well as synthetic
materials such as polyvinyl sponge (47), gelatin sponge (48), and
teflon-felt (49). These are now simply historical anecdotes and will
not be discussed further but the extensive work generated does
highlight the creativity that has gone into establishing a clinical
alternative to enterocystoplasty.
It was clear from the wide experience with intestinal augmenta-
tion that gastrointestinal tissue has fallen short in achieving these
ideals outlined by Marucci and Shoemaker on a number of levels.
Certainly the ability to create a capacious low-pressure reservoir
could reliably be achieved. The associated cost however was the
exposure to a variety of serious complications secondary to the
inherent physiologic differences between bowel mucosa and blad-
der epithelium. This has over the years given rise to a number of
innovative and clinically applicable techniques aimed at preserv-
ing the urothelium in order to maintain the physiologic integrity
of the reconstructed bladder epithelium.
URETEROCYSTOPLASTY
The natural characteristics of the ureter, namely its elasticity, a
wall of smooth muscle and a urothelial lining made it a very
attractive augmentation material. The first clinical report of urete-
rocystoplasty was published in 1973 by Eckstein and Martin who
described the use of a longitudinally incised ureter to augment the
bladder of a 7-month-old infant (50). The technique was revived
enthusiastically in the early 1990s by four independent groups and
was attractive on several levels (51–54). Since the urothelium was
preserved, acid–base disturbances and mucus production were not
a problem. Furthermore, the procedure could be performed using
an exclusively extraperitoneal approach. The inherent drawback
however was the limitation in its applicability. Suitable patients
had to have a dilated ureter serving a non-functioning kidney.
Technique had to be meticulous in order to preserve the renal
pelvis and ureteral blood supply. Observations derived from the
outcomes of enterocystoplasty dictated reconfiguration of the seg-
ment should be in the form of a U-shape in order to create a
sphere and maximize the final storage volume. The early results
were favorable with Landau and colleagues showing urodynamic
outcomes to be comparable to those of ileocystoplasty in an age-
matched control group. Specifically, the mean pressure specific
volume at 30 cm H2O was found to be 413 ml for the ileocysto-
plasty and 380 ml for the ureterocystoplasty groups respectively.
Bladder compliance was found to be normal in 87.5% of patients
following ureterocystoplasty (55). Similarly, favorable urodynamic
parameters have been reported by Nahas et al. in a cohort of
patients having undergone ureterocystoplasty and renal trans-
plantation (56). At mean follow-up of 50 months, no graft loss
was reported. They did not however, report the incidence of graft
dilatation in their patients. Johal et al. examined 17 patients under-
going ureterocystoplasty at a mean follow-up period of 4.5 years
(57). Urodynamic evaluation showed an improvement in mean
bladder capacity from 125 to 292 ml and in mean compliance from
2.1 to 16.2 ml/cm H2O. Four patients required reaugmentation.
Other groups have shown less favorable results and have
attempted to define criteria for successful ureterocystoplasty.
Hussman et al. prompted by their overall disappointing expe-
rience with ureterocystoplasty and the lack of definitive criteria
for patient selection, undertook a multi-institutional retrospec-
tive study examining the outcomes in 64 patients. Specifically,
they recommended that patient without reflux and either a single
or duplex collecting system could benefit from ureterocystoplasty
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if the ureter was at least 1.5 cm in diameter. Patients with reflux
improved only if the compliance of the total system was normal or
mildly non-compliant (compliance greater than 20 ml/cm H2O)
prior to augmentation. Detubularization and augmentation of the
bladder with a refluxing megaureter in the presence of poor com-
pliance was found to be of little benefit (58). Podesta and colleagues
similarly showed less favorable urodynamic outcomes with urete-
rocystoplasty in comparison to enterocystoplasty with both overall
final capacity and compliance being better in the enterocystoplasty
group (59).
The limitations of ureterocystoplasty in terms of applicability
remain an inherent issue. Early experimental work naturally tried
to address this. The earliest such report used a rabbit model and
described progressive dilatation of a normal sized ureter over a
30-day period by means of saline injections through a subcuta-
neously implanted injection port. Ureteral units were dilated by at
least 10-fold and augmentation cystoplasty performed with these
dilated ureteral segments increased bladder capacity by an average
of 260% (60). Later a similarly successful study evaluating ureteral
tissue balloon expansion using a pig model supported these results
(61). Although an interesting experimental work, the difficulty
faced with attempting the clinical application of techniques such
as these has yet to be circumvented. In an attempt to widen the
clinical application of ureterocystoplasty to a broader group of
patients, developments in surgical technique have been reported
that use segments of ureteral tissue derived from functioning kid-
neys (62–67). Techniques such as transureteroureterostomy (62)
or the creation of an ileal (65) ureter have been described to main-
tain drainage of the upper urinary tract. These may be technically
challenging and expose the upper urinary tract to a new spectrum
of potential complications such as obstruction, stones, metabolic
alterations, and possibly malignancy.
Overall the outcomes of ureterocystoplasty have been favorable
but the technique is not universally applicable and the ability to
reliably augment the bladder to the degree achieved by entero-
cystoplasty without reconstruction of the upper urinary tract has
not been conclusively demonstrated.
AUTOAUGMENTATION CYSTOPLASTY
The novel concept that excision or incision of the diseased detrusor
could be performed to create a urothelial diverticulum that could
serve to augment the bladder was first described by Cartwright
and Snow in 1989 (68, 69). Like ureterocystoplasty, the motivating
factor behind its development was the creation of a capacious and
compliant reservoir totally lined by urothelium. In the fact that
the procedure was extraperitoneal, had a shorter operative time
and did not affect the gastrointestinal tract added to its appeal.
The benefits of preserving the urothelium were clear but with the
increasing clinical experience that followed in subsequent years,
the reported urodynamic outcomes have varied. Some authors
have described only slight improvements in bladder capacity,
whereas others have noted improvements in capacity with per-
sistently high bladder pressures (70–72). In the series reported
by Stothers et al. (71) simple vesicomyotomy was performed
in their patients after earlier experimental work had suggested
detrusor excision offers no advantage over detrusor incision (73).
That same experimental work has shown that histologically the
autoaugmented area was characterized by a fibrous infiltrate with
an increase in thickness of 500% in comparison to the thickness
immediately after augmentation. Similarly, Garibay et al. noted
the development of a thin layer of fibrosis between the blad-
der mucosa and peritoneum, which possibly accounted for the
observed lack of improvement in bladder capacity in their animal
investigation (74). Cartwright and Snow reported on a combined
series of 25 patients several years after their original publication
and described their outcomes as encouraging but unpredictable.
Success was judged as good in 52%, acceptable in 28%, and poor
in 20%. Those patients requiring reaugmentation were found to
have a layer of collagen laid down over intact urothelium in the
area of the original procedure (75).
Several series have reported poor success rates in patients with
neurogenic bladder dysfunction (76–79). MacNeily et al. found
the short term outcomes promising but unfortunately not durable
(79). Twelve of 17 patients were considered failures as a result of
ongoing incontinence or ongoing upper tract deterioration. Marte
et al. suggested that the mechanism of action with autoaugmen-
tation might be a direct effect on the ability of the detrusor to
contract rather than augmentation of bladder volume. The authors
felt that the patients most likely to benefit are those with primary
detrusor instability and a high leak-point pressure (78). Gurocak
et al. reviewed the long-term results of autoaugmentation looking
at 150 published studies (80). They found that better compliance
after autoaugmentation procedures seems to be less pronounced
and of shorter duration than that of conventional enterocysto-
plasty. The best candidates seemed to be those with a close to
normal capacity and poor compliance. It appears that the best
outcomes can be expected in those patients with good capacity
(greater than 75% of that expected) but poor compliance.
Bladder autoaugmentation offers an extraperitoneal surgical
approach, low morbidity, and urothelial preservation but has
unfortunately not lived up to the initial enthusiasm it generated.
Over the years its general applicability has narrowed in scope
with the clinical experience suggesting that best results seem to
be obtained in a select group of patients. Furthermore, the overall
increases in bladder volume that can be reliably obtained do not
approach those obtained by conventional enterocystoplasty and in
the long-term the outcomes do not appear as durable.
SEROMUSCULAR ENTEROCYSTOPLASTY
The efforts to develop the ideal material for bladder augmenta-
tion made significant advances with elimination of the metabolic
complications associated with the incorporation of bowel into
the urinary tract. Both ureterocystoplasty and autoaugmentation
made use of the ideal tissue to eliminate these issues and were
significant technical developments. They eliminated most of the
major disadvantages of enterocystoplasty. Unfortunately clinical
experience fell short in terms of the general applicability of these
techniques and the reliability of the degree of augmentation that
could be achieved. Any new technique should continue to be reli-
able in addressing the primary clinical goal in question and that
is the creation of a capacious low-pressure reservoir to protect the
upper urinary tract and establish urinary continence.
Seromuscular enterocystoplasty was developed with the intent
of combing the benefits of urothelial preservation with those of
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intestinal augmentation. Urothelial preservation would eliminate
the metabolic complications associated with enterocystoplasty and
the intestinal segment would more reliably augment the bladder.
The early experimental work will not be reviewed here in depth but
it would suffice to say that the results were encouraging but viewed
with cautious optimism. The early experimental work had been
performed using denuded segments of bowel or denuded segments
grafted with a patch of bladder mucosa to augment the bladder
after total or subtotal cystectomy (37, 38, 81, 82). After a criti-
cal review of the technique by Koontz et al. where they concluded
that the complication rate was high and the clinical application has
limited usefulness work on the technique was largely abandoned.
He felt that the clinical application has limited usefulness (83).
The idea was resurrected in 1988 when Oesch, using a rat model,
demonstrated successful overgrowth of the denuded bowel surface
with urothelium when demucosalized segments of cecum were
anastomosed to the bladder following subtotal cystectomy (84).
Pippi Salle et al. attempted to duplicate these experiments in dogs
but the colonic patches from which the mucosa had been stripped
underwent severe contraction and fibrosis in contact with urine
(85). Similar outcomes using a rat and dog model were obtained by
Gonzalez and his team (86, 87). Urothelial regrowth would occur
in a small animal model but not in the large animal model. The
poor experimental results obtained with partial detrusorectomy
to increase bladder capacity prompted the development of a dog
model in which the detrusor was removed with preservation of the
urothelium (88). The resulting diverticulum was then covered with
a reconfigured segment of sigmoid colon from which the mucosa
had been removed. Preservation of the bowel submucosa was
essential to avoid contraction of the colonic segment. Histological
evaluation revealed that the composite organ was composed of
the seromuscular and submucosal layer of the colon covered with
transitional epithelium. Lima et al. described a similar operation
and also obtained encouraging results (89). They subsequently
went on to develop a dog model for seromuscular ileocystoplasty
whereby a patch of demucosalized ileum was used to replace the
whole bladder. Bladder configuration was maintained by the use of
a silicone balloon placed within the augmented bladder and sim-
ilarly encouraging results were obtained (90, 91). Dewan and his
group took a different but similarly successful approach and used
demucosalized stomach patches in combination with urothelial
preservation (92).
Dewan and Stefanek published the first clinical application
of seromuscular colocystoplasty. They reported on a 9-year-old
girl with myelomeningocele who achieved an increase in bladder
capacity from 40 to 213 ml, an increase in compliance from 1 to
14 ml/cm H2O, and was totally continent on a regimen of clean
intermittent catheterization every 3 h (93). Overall, the clinical
experience has been positive as reported by a number of other
groups. The clinical experience with seromuscular colocystoplasty
lined with urothelium (SCLU) in 16 patients reported by Gonza-
lez and his group showed a 2.4-fold increase in bladder capacity.
Two patients failed augmentation and required ileocystoplasty.
Two of thirteen patients with incontinence remained incontinent
and there were no patients with metabolic acidosis or electrolyte
abnormalities. Urothelial biopsies in 10 patients showed exclu-
sively urothelium in 7 (94). Jednak et al. reported on another group
of 32 patients followed for a mean period of 1.6 years and showed
that total bladder capacity and capacity at 30 cm H2O increased by
1.8- and 2.4-fold respectively. This was irrespective of how bladder
capacity was calculated. Achieving continence generally required
a bladder neck procedure. All but two patients achieving con-
tinence had undergone a bladder outlet procedure prior to, at
the time of, or following augmentation. An hourglass deformity
developed in 22%, 12.5% failed augmentation, and 6% developed
bladder calculi. New onset or increased hydronephrosis and reflux
were seen in 10 and 15% of evaluated renal units respectively.
The majority of patients developing upper tract dilatation either
failed augmentation or developed an hourglass deformity. Colonic
mucosal regrowth to varying degrees was seen in five of seven inter-
pretable biopsies. Two patients had only transitional epithelium.
There were no bladder perforations, metabolic abnormalities did
not develop, and mucus production was not clinically significant
(95). Bandi et al. reported longer-term outcomes on some of the
patients undergoing SCLU in the early clinical experience of Gon-
zalez and his group. These were compared to a group of children
undergoing either colocystoplasty or ileocystoplasty. They found
the SCLU patients were at a decreased risk of bladder perforation
and bowel obstruction but were otherwise not devoid of other
long-term complications such as vesicoureteral reflux, bladder cal-
culi, and augment failure. There was no long-term metabolic data
provided (96).
The main prerequisite for success appears to be that bladder dis-
tension be maintained in the post-operative period. This appears
to be the determinant of hourglass deformities as well as outright
failures. As a consequence, the procedure is not recommended in
those patients undergoing any additional procedure that requires
opening the bladder thus limiting its applicability to patients
requiring creation of a continent catheterizable channel at the
same time. It has been recommended that continent catheterizable
channels if required be done as a second procedure (97).
The clinical experience with both colon and ileum has been
outlined with some variation in technique by Lima and his group
in several reports. After initially using the urothelial preserving
technique in combination with sigmoid colon (89), the group
opted to abandon urothelial preservation and simply distend the
augmented bladder post-operatively via placement of a silicone
intravesical mold. The ureters were diverted for a 2-week period
at which point both the ureteral stents and bladder mold were
removed. The first report published looked at the results with
colon in 24 patients. Overall the mean improvement in bladder
capacity was fourfold. In absolute terms however the preoperative
bladder capacity was 100 ml or less in all but two patients and post-
operatively 15 of 24 patients achieved a bladder capacity of 200 ml
or less. Compliance was reported as improved but specifics were
provided. No mucus production was noted. Continence rates were
excellent for patients with neurogenic bladder but disappointing
for patients with bladder exstrophy. Data with respect to metabolic
evaluation and upper tract deterioration were not reported (98).
The only additional procedure performed at the time of augmen-
tation in some of the patients was the placement of an artificial
urinary sphincter.
Lima et al. later reported on their clinical experience in 25
patients undergoing ileal seromuscular cystoplasty using the same
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silicone mold technique (99). It is not clear if any of the patients
underwent concomitant procedure at the time of augmentation.
The overall percent increase in capacity was encouraging but the
majority of patients had a reported final augmented capacity of
less than 200 ml and changes in the upper urinary tract over time
in this group of patients was not reported (99). Lima and his group
also found that bladder distension is critical to achieving optimal
results. Patients undergoing seromuscular augmentation without
placement of an intravesical mold for the post-operative period
typically did worse.
The clinical experience with gastric segments for seromuscu-
lar enterocystoplasty has been variable. The initial report on a
very small group of patients by Dewan and Stefanek found that
increases in bladder volume and compliance were not as impressive
as with enterocystoplasty (100). The results were evaluated at 3 and
12 months post-operatively. Carr et al. reported variable results in
a group of 13 patients with a mean follow-up of 50 months (101).
They described their results as good in five, fair in four, and poor
in four. Several techniques were used to ensure coaptation of the
seromuscular segment and the urothelium in this group. These
included simply the placement of a Jackson-Pratt drain between
the seromuscular and urothelial layers, maintaining the bladder in
a semi-distended state by adjusting the height of the Foley drainage
bag, or the placement of an intravesical balloon to mechanically
keep the bladder distended. It is not clear if the outcomes showed
any relationship to the type of technique used to maintain coap-
tation in the post-operative period. As with other groups ancillary
procedures were performed using an extravesical technique.
Seromuscular enterocystoplasty has certainly come closest to
achieving augmentation with a tissue that maintains urothelial
integrity and has a supporting muscular layer. At least one study
however has suggested that there are no long-term differences
in terms of vesicoureteral reflux, bladder calculi, or augmenta-
tion failure. Although it would inherently seem that metabolic
derangements would not be an issue even in the long-term, meta-
bolic assessments have nor been consistently reported. Limitations
have also come to light. The parameters for a successful outcome
limit some surgical techniques to those patients in which no con-
comitant intravesical procedures needs to be performed at the
time of augmentation. Other techniques require a prolonged post-
operative period of ureteral drainage and bladder distension using
a silicone mold. Furthermore it has not been reported as to how an
additional procedure such as ureteral reimplantation or the cre-
ation of a catheterizable channel are reliably performed using the
silicone mold technique.
BLADDER TISSUE ENGINEERING
Urinary tract reconstruction has evolved to the point where it
is now possible to effectively establish continence and prevent
upper urinary tact deterioration. The goal of simply improving
the bladder’s function as a reservoir has evolved beyond this as
the limitations and complications associated with incorporation
of gastrointestinal tissue into the urinary tract has become appar-
ent and the physiologic mechanisms underlying these understood.
Remarkable advancements in techniques for bladder augmenta-
tion have been developed initially with great enthusiasm but as
clinical experience has accumulated all have been shown to have
limitations to some degree. These have included a lack of general
applicability, the use of tissues with limitations in availability,
technical surgical challenges, and unreliable outcomes. Given the
technological limitations in basic science at the time, the hope
was at best to duplicate bladder tissue and urothelial physiol-
ogy and not reconstitute the bladder. Through developments in
tissue engineering, however, previously unattainable goals have
become a possibility. For the most part, the early clinical advance-
ments focused on limiting physiologic derangements associated
with augmentation by attempting to maintain urothelial integrity
since this was after all the source of the majority of complications.
The potential to reliably restore the functional aspects of the detru-
sor were out of reach. They could be mimicked to a small degree
but this fell far short of the normal state. We could not repro-
duce the characteristics of the intricate arrangement of smooth
muscle, nerves, and blood vessels. The bladder is a complex organ
composed of a specialized urothelium and a compliant detrusor.
It functions as a low-pressure, high-capacity reservoir that can
empty completely. This in turn is modified by and responds to
direct conscious input. At the bladder level, this requires complex
interplay that occurs on multiple levels including neural pathways,
the bladder smooth muscle, the urothelium, and the sphincteric
components of the bladder outlet. Developments in tissue engi-
neering have allowed us to look toward the possible replacement of
complex bladder function in situations where this ability has been
lost. This has come about through progress at a multidisciplinary
level with advancements in fields such as biology, medicine, and
engineering (102, 103).
Tissue engineering has four requirements and those are the
presence of adequate stem/progenitor cells, an appropriate extra-
cellular matrix or carrier construct, an appropriate blood supply,
and the presence of regulatory signals (104).
Two approaches can be used. The acellular approach makes use
of scaffolds to enhance the body’s natural ability for self-repair.
These assist in determining the direction of new tissue growth.
This can pose a problem when the tissue from which regeneration
is required is itself diseased. The cellular approach makes use of
donor cells to seed the scaffold. This creates a variety of options
from which cells can be derived. These can be autologous, allo-
geneic, or heterologous. Immunogenicity is a concern however.
The best option remains autologous cells since this eliminates the
possibility of rejection. Current research is focused on two areas:
determining the most appropriate cells for bladder regeneration
and designing the best scaffolds to reproduce the physiology and
function of the tissue being replaced (105). The cells in particular
should be readily available, easily harvested, and have the ability to
regenerate a normal bladder. There are concerns that cells derived
from a diseased bladder may not be able to revert to normal and
as such the use of stem cells for this purpose is being extensively
investigated (106, 107).
Scaffolds are tissues designed to support cell growth and can be
natural or synthetic. Naturally derived scaffolds are derived form
autologous, allogeneic, or xenogeneic tissues that are processed
by chemical or mechanical means in order to remove the cellu-
lar components. Although stripped of their cellular element, they
still maintain important extracellular matrix components such
as collagen, fibronectin, laminin, glycosaminoglycans, and growth
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factors that can stimulate the regeneration of smooth muscle and
urothelial cells by promote cell migration, growth, and differen-
tiation. These matrices can still retain some of their cellularity
however and can potentially expose recipients to immunogenic
components (102). Synthetic scaffolds have been developed as an
alternative. These are biodegradable polymers constructed into
a mesh able to support and direct tissue in growth and prolifera-
tion. Their synthetic nature allows for the precise reproducibility of
their composition. They do however lack the inherent biochemical
components that direct tissue regeneration and neovasculariza-
tion. The incorporation of these compounds into the scaffold
is possible but regulating their release in a controlled fashion is
an unresolved issue. The most commonly used compounds used
for synthetic scaffolds are poly-α-esters such as poly(l-lactide),
polyglycolic acid, and poly(lactide-co-glycolic acid) (104, 108).
The two natural products that have generated the most enthu-
siasm are porcine small intestinal submucosa (SIS) and bladder
acellular matrix (BAM) (108). The results with each have been
mixed however. Kropp et al. analyzed outcomes using a dog model
in which they performed partial cystectomy and immediate graft-
ing with acellular SIS. Evaluations times were set at 1, 3, 6, and
15 months. Histologically, all the tissue layers (mucosa, serosa,
muscle) showed evidence of regeneration (109). Further assess-
ment of the regenerated bladder tissue showed that the compliance
was no different from that of control bladders and contractility
studies showed a contractile response and innervation similar to
that of a normal canine bladder (110). These were studies in nor-
mal bladders however. When similar studies were performed in
damaged bladders following the removal of more than 90% of
the detrusor, the results were less encouraging. There was limited
bladder regeneration and the grafts were characterized by a central
abundance of inflammatory cells and fibroblasts with few smooth
muscle cells, poor vascularization, adhesions, and shrinkage. Some
grafts even had bone and calcification at the graft site. It appeared
that bladder regeneration in this model had limitations dependant
on the state of the diseased bladder. Regeneration was dependant
on the revascularization rate and the degree of pre-existing bladder
injury (111).
Bladder acellular matrix was first used for bladder augmen-
tation as an autologous acellular graft in rats by Probst et al.
(112). The scaffold, prepared from the bladder dome of rats and
consisting of primarily collagen and elastin, was used to imme-
diately augment normal rat bladders following hemicystectomy.
The animals were sacrificed at various time points with the latest
being 20 weeks following surgery. The authors observed ingrowth
of all bladder wall components as well as neural regeneration with-
out signs of rejection. At 12 weeks post-operatively it was in fact
difficult to distinguish the junction between native and regener-
ated bladder wall. Bladder capacity was preserved in the animals.
Further evaluation went on to demonstrate that this regenerated
tissue exhibited contractile activity in response to electrical field
stimulation and a quantitatively identical pattern of response to
nitric oxide and muscarinic, purinergic, and α- and β-adrenergic
drugs. Histological and immunohistochemical studies confirmed
the presence of receptors to these compounds (113). The sub-
sequent evaluation of acellular BAM xenotransplants prepared
form dog, rabbit, and hamster and grafted into rats had similarly
encouraging results with the grafts promoting both functional
and morphological regeneration of the bladder (114). The allo-
graft technique was then transferred to a larger porcine model
with promising initial results. At 8–12 weeks the grafts showed
repopulation with all cellular components and on average had con-
tracted by 25% (115). Outcomes at a longer time frame of 22 weeks
post-operatively were disappointing however. Grossly there was
macroscopic contracture of the grafts with only peripheral cel-
lular repopulation. The central portions of the graft showed no
evidence of smooth muscle bundles or urothelium (116). Once
again the success seemed to be dependant on model size and to a
significant degree on the rate and efficiency of neovascularization.
Seeding scaffolds with the cellular components necessary for
bladder regeneration was developed as a means to promote a
more rapid and diffuse distribution of cells across the scaffold
which is then implanted into the host. Since the technique does
not depend on tissue revascularization and ingrowth from the
host, a more complete and efficient regenerative process might be
expected in grafts of larger size. Work using both synthetic and nat-
ural grafts has been mixed. Early work published by Yoo et al. used
seeded and unseeded allogeneic bladder submucosa and showed
better outcomes in the seeded group which demonstrated normal
cellular organization and less graft shrinkage (117). A different
outcome was reported by Zhang et al. who found that seeded SIS
grafts demonstrated limited regeneration and were characterized
by shrinkage and adhesions (110). This was no different from the
outcomes achieved using unseeded SIS grafts. Jayo and colleagues
subsequently used synthetic scaffolds seeded with autologous
urothelial and smooth muscle cells in dogs and observed better
outcomes in the seeded versus unseeded groups. Characterization
of the healing responses indicated that seeded grafts elicited an
early healing process that led to regeneration of both mucosa and
muscle whereas unseeded grafts stimulated a reparative response
leading to incomplete tissue layer development (118).
The most advanced work has been generated by Atala and
his group who were the first to reconstitute the bladder in
a canine model undergoing trigone-sparing cystectomy (119).
Transplantable neo-organs were cultured in vitro from synthetic
scaffolds seeded with urothelial and muscle cells. Functional eval-
uations up to 11 months revealed a normal architecture, normal
capacity to retain urine, and normal elastic properties. This trans-
fer of this technology eventually resulted in a clinical human
study in nine patients with myelomeningocele (120). The tissue
used to seed the scaffolds was derived from the patients them-
selves. Patients received either a scaffold of collagen or a composite
scaffold of collagen and polyglycolic acid. Three patients had an
omental wrap to promote vascularization. Results were reported in
seven patients with a mean follow-up of 46 months. Four patients
were evaluated as far out as 49–61 months post-operatively. No
metabolic derangements developed, renal function was preserved,
there was no mucus production, and no calculi developed. All
patients were incontinent preoperatively but it is not clear from
the results how many patients achieved a socially acceptable level
of continence post-operatively. No upper urinary tract follow-
up post-operatively was reported. The improvements in bladder
capacity were not analogous to those that can be achieved by stan-
dard enterocystoplasty techniques however. One patient developed
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a reduction in capacity and one improved from 139 to 480 ml. The
improvement in capacity in the remaining patients ranged from
12 to 108 ml. Three patients had undergone an omental wrap to
promote vascularization and these tended to have a better urody-
namic outcome. The best improvements in compliance (2.8-fold)
were seen in composite bladders wrapped with omentum. Pres-
sure specific volumes at 30 and 40 cm H2O were not reported. One
patient underwent a reoperative cystoplasty 4 years after surgery.
This work was an important step in evaluating the transfer of tis-
sue engineering technology to the clinical setting and the results
can be viewed with some degree of optimism but certainly do not
improve on the outcomes seen with many of the earlier developed
augmentation techniques.
CONCLUSION
The area of bladder augmentation has made remarkable advances
over the last 100 years. Initially a purely surgical problem, finding
the ideal tissue is now being addressed using a multidisciplinary
approach. We have gone from harvesting tissue to tissue regen-
eration. We have progressed from simply improving a reservoir
to sitting on the threshold of reconstituting a normal organ in
humans. Despite our advances however the ideal tissue and tech-
nique for augmentation remains elusive. At present clinical experi-
ence suggests that standard bladder augmentation techniques offer
the most reliable patient outcomes and should be the first choice
for patients. The challenge to improve remains and the future
holds promise for revolutionary new developments as research
and technical innovations open the door to new frontiers.
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